Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)

[1]  H. Friess,et al.  Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma. , 2021, Histology and histopathology.

[2]  C. Luchini,et al.  Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. , 2021, The British journal of surgery.

[3]  M. Mino‐Kenudson,et al.  Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems , 2020, Scientific Reports.

[4]  A. Krasinskas,et al.  Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy , 2020, Modern Pathology.

[5]  Song-Cheol Kim,et al.  Management of isolated recurrence after surgery for pancreatic adenocarcinoma , 2019, The British journal of surgery.

[6]  J. Berlin,et al.  APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. , 2019, Journal of Clinical Oncology.

[7]  E. Nakakura,et al.  Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? , 2019, The American journal of surgical pathology.

[8]  G. Honda,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.

[9]  M. Reni,et al.  A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. , 2018, European journal of cancer.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  V. Torri,et al.  Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. , 2018, The lancet. Gastroenterology & hepatology.

[12]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  H. Friess,et al.  The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. , 2017, Cancer treatment reviews.

[14]  G. Gravante,et al.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma , 2017, Annals of the Royal College of Surgeons of England.

[15]  Jeffrey E. Lee,et al.  Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival , 2016, The American journal of surgical pathology.

[16]  M. Reni,et al.  Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma , 2016, British Journal of Cancer.

[17]  N. Dhani,et al.  The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes , 2016, Journal of Clinical Pathology.

[18]  A. Krasinskas,et al.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas , 2015, The American journal of surgical pathology.

[19]  D. Gouma,et al.  Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). , 2014, Surgery.

[20]  R. Langer,et al.  Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant Treatment , 2013, Front. Oncol..

[21]  Jeffrey E. Lee,et al.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma , 2012, Cancer.

[22]  Jeffrey E. Lee,et al.  Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2012, The American journal of surgical pathology.

[23]  B. Eisenberg,et al.  Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. , 1998, The American surgeon.

[24]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[25]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[26]  T. Teshima,et al.  Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region , 1989, Journal of surgical oncology.

[27]  C. Fiorino,et al.  Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  J. S. Karlsson,et al.  Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. , 2015, Cancer treatment reviews.

[29]  A. Krasinskas,et al.  Assessing treatment effect in pancreatic cancer. , 2012, Archives of pathology & laboratory medicine.

[30]  M. Reni,et al.  A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) , 2011, Cancer Chemotherapy and Pharmacology.

[31]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.